Abstract
Tufts researchers have demonstrated that peptide boronic acid inhibitors of DPP-4 could be safe and effective treatments for diabetes and Arisaph Pharmaceuticals already has one of the compounds in Phase I testing. But developers will have to keep an eye on the off-target effects of these potent compounds.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.